Read my latest thoughts…….

My name is James, and this is my personal blog about finances, the stock market, and investments. This blog is for me to document, learn and improve as an investor. Think of it as a diary or an investing journal.

If you do think this blog can help you as an investor, please subscribe, and you can be emailed my latest thoughts completely free, although donations are accepted. Cash App: $Randominvestor

Disclaimer: I am not a financial advisor. Take anything I say for entertainment purposes only.

Latest from the Blog

← Back

Thank you for your response. ✨

The Short Trap of the Decade: Why Wall Street Still Doesn’t Understand Moderna’s Second Act

Every few years, the financial commentariat suffers from a collective failure of imagination. When a beaten-down stock catches fire, the reflexive reaction from spreadsheet purists is depressingly predictable: dismiss the rally, call the valuation absurd, and hunt for an entry to short. Right now, that exact mistake is happening in real time with Moderna (MRNA).…

6 Things to Understand About Moderna’s Melanoma mRNA Vaccine

1. This is an Operating System, Not a Pill: mRNA-4157 (Intismeran autogene) is not a generalized product you pull off a shelf. It is an algorithmic manufacturing pipeline. Moderna and Merck ingest raw, unstructured local data (a patient’s tumor sample), run it through a massively parallel sequencing workflow, and output a customized synthetic mRNA sequence…

Why Vertex is the Nvidia of Life Sciences

When the market looks at large-cap biopharma, it sees two uninspiring archetypes: bloated, debt-heavy legacy conglomerates milking aging blockbusters, or single-theme obesity plays trading at nosebleed valuations. What the market fundamentally misprices in Vertex Pharmaceuticals (VRTX) is the biological equivalent of Nvidia’s CUDA ecosystem. Years ago, Nvidia was dismissed as a high-margin PC graphics chipmaker,…